Oncology Best Practice™: From Trials to Clinical Practice: Understanding the Latest Evidence for the Treatment of Myelodysplastic Syndromes

In order to request this CME/CE activity for your center, please contact Samantha Zelasko at SZelasko@gotoper.com

Start date: April 30, 2021

Upcoming Events

DateTimeInstitutionLocation
(City, State)		Speaker
2/3/20227:30 am - 8:30 am ETEinstein Medical CenterPhiladelphia, PADavid Sallman, MD

Overview

The management of myelodysplastic syndrome (MDS) has advanced rapidly in recent years, with new treatment approaches for symptoms and disease control. However, translation of clinical trial data into practice remains a significant challenge, particularly in the community setting, where clinicians may see only sporadic cases of MDS.

The goal of this Oncology Best Practice™ series is to provide up-to-date recommendations for risk stratification and management of MDS to hematology/oncology professionals, as well as treatments on the horizons for these hematologic malignancies. This series of live, virtual meetings will include multiple formats for learning, including data presentations, case presentations, and faculty Q&A.

Benefits of Attending

  • Get up-to-date with risk stratification for MDS
  • Discuss practical challenges for management of MDS with expert faculty
  • Learn about the latest research into emerging treatment options for MDS
  • Engage with case scenarios to enhance your knowledge of best practices in MDS management

Acknowledgment of Commercial Support

This activity is supported by educational grants from Bristol Myers Squibb, Novartis Pharmaceuticals Corporation, and Taiho Oncology.

Target Audience

This educational activity is directed toward hematology/oncology physicians, pathologists, oncology nurses, and other health care professionals involved in the treatment of patients with MDS.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Summarize the criteria for MDS diagnosis and methods for risk stratification
  • Explain the impact of risk assessment on treatment selection in patients with MDS
  • Assess the efficacy and safety profiles for current and emerging agents/combinations in patients with MDS
  • Evaluate recent evidence from landmark trials within the context of current treatment paradigms for patients with MDS

Chair

Guillermo Garcia-Manero, MD

Guillermo Garcia-Manero, MD
McCredie Professor of Medicine
Chief, Section of MDS
Vice Chair, Dept. of Leukemia
University of Texas
MD Anderson Cancer Center
Houston, TX

Amy E. DeZern, MD, MHS

Amy E. DeZern, MD, MHS
Associate Professor of Oncology and Medicine
Division of Hematologic Malignancies
The Johns Hopkins University School of Medicine
Baltimore, MD

Elizabeth A. Griffiths, MD

Elizabeth A. Griffiths, MD
Associate Professor of Medicine, Leukemia Section
Associate Director for Early Phase Clinical Trials, Hematology
Roswell Park Comprehensive Cancer Center
Associate Professor
State University of New York at Buffalo
Buffalo, NY

Rami Komrokji, MD

Rami Komrokji, MD
Senior Member, Vice Chair
Section Head – Leukemia & MDS
Department of Malignant Hematology
Moffitt Cancer Center
Professor of Oncologic Sciences
University of South Florida
Tampa, FL

Jamile Shammo, MD, FASCP, FACP

Jamile Shammo, MD, FASCP, FACP
Professor of Medicine and Pathology
Director of the MDS/MPN/AA Program
Section of Hematology
Rush University Medical Center
Chicago, IL

Accreditation/ Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.